GlassScriptPhysician profile
Joseph L Reese
NPI 1730152265
$18,388.15
in general payments reported to CMS, 2019-2025
67 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,960 · 2020: $1,505 · 2021: $2,466 · 2022: $2,616 · 2023: $3,238 · 2024: $2,857 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,820 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,820.24 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,982.31 | 2019-2025 | |
| Novo Nordisk INC | $1,525.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,313.81 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,015.08 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Amgen INC. | $949.49 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $913.89 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Glaxosmithkline, LLC. | $907.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $878.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $876.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $676.39 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $627.47 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $588.51 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $491.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $482.31 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $480.51 | 2019-2025 | Xifaxan, Trulance, Relistor |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Reese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.